CD44 and pancreatic neoplasm: Pancreatic CSCs (PCSCs), that represent approximately 0.5-1% of pancreatic cancer cells (67), are characterized by the expression of the surface markers CD44+/CD24+, CD133+ and ESA+, and their presence is associated with poor prognosis (68).